Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib

European Journal of Cancer

Volumn 46, Issue 11, 2010, Pages 2045-2051

  McKibbin, Trevor ^a   Zhao, Wei ^b   Tagen, Michael ^b   Daw, Najat C ^b   Furman, Wayne L ^b   McGregor, Lisa M ^b   Geyer, J Russell ^c   Allen, Jeffrey W ^a   Stewart, Clinton F ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

EGFR; Gefitinib; Paediatric cancer; Pharmacogenomics; Polymorphisms; Skin rash

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IRINOTECAN;

ADOLESCENT; ARTICLE; BRAIN STEM TUMOR; CANCER CHEMOTHERAPY; CHILD; DIARRHEA; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLIOMA; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SOLID TUMOR;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DIARRHEA; DRUG ERUPTIONS; EXANTHEMA; GERM-LINE MUTATION; HUMANS; INFANT; NEOPLASMS; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; YOUNG ADULT;

EID: 77954218609     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.05.007     Document Type: Article

References (30)

1. J. Mendelsohn Targeting the epidermal growth factor receptor for cancer therapy J Clin Oncol 20 2002 1S 13S
2. B. Brandt, S. Meyer-Staeckling, and H. Schmidt Mechanisms of EGFR gene transcription modulation: relationship to cancer risk and therapy response Clin Cancer Res 12 2006 7252 7260
3. R.S. Herbst, M. Fukuoka, and J. Baselga Gefitinib - a novel targeted approach to treating cancer Nat Rev Cancer 4 2004 956 965
4. M.G. Kris, R.B. Natale, and R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
5. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
6. F. Cappuzzo, F.R. Hirsch, and E. Rossi Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 2005 643 655 (Pubitemid 40812628)
7. D.A. Haas-Kogan, M.D. Prados, and T. Tihan Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib J Natl Cancer Inst 97 2005 880 887
8. S.W. Han, T.Y. Kim, and P.G. Hwang Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2005 2493 2501
9. R. Perez-Soler, A. Chachoua, and L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
10. V. Gregorc, M. Hidalgo, and A. Spreafico Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib Clin Pharmacol Ther 83 2008 477 484
11. C.L. Huang, C.H. Yang, and K.H. Yeh EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment Lung Cancer 64 2009 346 351
12. G. Liu, S. Gurubhagavatula, and W. Zhou Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib Pharmacogenomics J 8 2008 129 138
13. C.M. Rudin, W. Liu, and A. Desai Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity J Clin Oncol 26 2008 1119 1127
14. W. Liu, F. Innocenti, and M.H. Wu A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter Cancer Res 65 2005 46 53
15. M.L. Amador, D. Oppenheimer, and S. Perea An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors Cancer Res 64 2004 9139 9143
16. H. Buerger, J. Packeisen, and A. Boecker Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence - first results of an inter-ethnic breast cancer study J Pathol 203 2004 545 550
17. T. Moriai, M.S. Kobrin, and C. Hope A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling Proc Natl Acad Sci USA 91 1994 10217 10221
18. M. Nomura, H. Shigematsu, and L. Li Polymorphisms, mutations, amplification of the EGFR gene in non-small cell lung cancers PLoS Med 4 2007 e125
19. N.C. Daw, W.L. Furman, and C.F. Stewart Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study J Clin Oncol 23 2005 6172 6180
20. B.B. Freeman 3rd, N.C. Daw, and J.R. Geyer Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients Cancer Invest 24 2006 310 317
21. W.L. Furman, F. Navid, and N.C. Daw Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors J Clin Oncol 27 2009 4599 4604
22. Cancer Therapy Evaluation Program CTCAE, version 2.0, DCTD, NCI, NIH, DHHS .
23. Cancer Therapy Evaluation Program CTCAE, version 3.0, DCTD, NCI, NIH, DHHS .
24. W. Zhang, M. Gordon, and A.M. Schultheis FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab J Clin Oncol 25 2007 3712 3718
25. I. Ross, and G.R. Robert A language for data analysis and graphics J Comput Graph Stat 5 1996 299 314
26. S.W. Han, Y.K. Jeon, and K.H. Lee Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer Pharmacogenet Genomics 17 2007 313 319
27. E. Bandres, R. Barricarte, and C. Cantero Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients Oral Oncol 43 2007 713 719
28. W. Zhang, D.J. Park, and B. Lu Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation Clin Cancer Res 11 2005 600 605
29. W.S. Wang, P.M. Chen, and T.J. Chiou Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma Clin Cancer Res 13 2007 3597 3604
30. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957